Johnson & Johnson has now announced the global phase 3 human trials of its version of the coronavirus vaccine. Compared to others, this vaccine is a one-shot drug that may mark America's first in the medicinal area. The trial is expected to invite at least 60,000 volunteers and may soon allow the company to seek emergency authorization next year.
COVID-19 vaccine update
Most of the vaccines (other than COVID vaccines) require more than one dose shot on each human being. Hospitals do an annual test in order for it to be effective.
So can J&J push through with their original plan? Early studies say yes.
According to the report, the drug's early experiments were seen effective with non-human primate models (NHP). Six of the NHPs received single immunization with the drug and had shown no detectable virus in the lower respiratory tract despite exposure to SARS-CoV-2.
Johnson & Johnson is expected to seek emergency authorization from the government early next year.
This article is owned by Tech Times
Written by Jamie Pancho
